

IGBA - MOPI CONFERENCE 2022

GENERIC AND BIOSIMILAR MEDICINES, CENTRAL TO PATIENT HEALTH AND GLOBAL HEALTHCARE POLICIES

THE CONFERENCE WILL SHOWCASE TOPICS AT GLOBAL, ASIA & ASEAN LEVEL

7 September 2022 (Wednesday) - Half day

Time	Agenda
2.00pm - 3.00pm	Registration and Welcoming Coffee & Tea
3.00pm - 4.00pm	Opening Ceremony of IGBA - MOPI Conference 2022 by YB Khairy Jamaluddin, Minister, Ministry of Health, Malaysia
4.00pm - 4.30pm	Coffee & Tea Break + Press Conference
4.30pm - 6.00pm	<p>SESSION 1 - COVID-19 and beyond: patients first, investing in health for all</p> <p>The Covid-19 pandemic has highlighted the centrality of health to global well-being and the global economy. Global recovery efforts should now leverage this unprecedented situation to emphasize that financing health is a long-term investment. This will ensure the steady progress of United Nations Sustainable Development Goal 3, which seeks to ensure health for all and addresses all major health priorities, including communicable, non-communicable and environmental diseases, universal health coverage, and access for all to safe, effective, quality, and affordable medicines and vaccines. During this session, international organizations, governments and industry will describe the impact that COVID-19 has had on public health and the investment needed to ensure access around the world.</p>

Chair of the Session

Vivian Fritelli

Chief Executive, Generic and Biosimilar Medicines of Southern Africa (GBM), South Africa
Chair, International Generic and Biosimilar Medicines Association (IGBA), Switzerland

Speakers of the Session

Investment in local and global health systems: An investment in the future

Dr Mariângela Batista Galvão Simão

Assistant Director-General

Drug Access, Vaccines and Pharmaceuticals

World Health Organization (WHO), Switzerland

Post COVID-19 action plan:

Investment in a resilient national healthcare system

Tan Sri' Dato' Seri Dr Noor Hisham bin Abdullah

Director General of Health

Ministry of Health, Malaysia

Industry experience with handling the pandemic and recommendations for future-proofing healthcare systems in Europe: A regional industry association's perspective

Dr. Adrian van den Hoven

Director General

Medicines for Europe, Belgium

Industry experience with handling the pandemic and measures for the future: The Indian pharmaceutical alliance's perspective

Archana Jatkar

Associate Secretary General

Indian Pharmaceutical Alliance (IPA), India

7.00pm - 8.30pm

Welcoming Cocktail @ Kuala Lumpur Tower

8 September 2022 (Thursday) - Full day

Time	Agenda
8.00am - 9.00am	Welcoming Coffee & Tea
9.00am - 9.30am	Keynote Address by YBhg. Datuk Lokman Hakim Ali, Secretary General of Ministry of International Trade and Industry (MITI), Malaysia
9.30am - 11.00am	SESSION 2 - South East Asian market: The SEA market is one of the fastest growing pharmaceutical markets in the world.
	This session provides an update on the generic and biosimilar challenges and opportunities in Southeast Asia, including the impact of the COVID-19 pandemic on patient access to medicines, the overall market and the industry.

Chair of the Session

Billy Urudra
President
Malaysian Organisation of Pharmaceutical Industries (MOPI), Malaysia

Speakers of the Session

Update on SEA pharma market

Jonathan Roberts
General Manager of Malaysia, Singapore & Vietnam
IQVIA, Singapore

Impact of the pandemic on the SEA market

Dr. Khor Swee Kheng
Chief Executive Officer
Angsana Health, Malaysia

Challenges & opportunities of the SEA pharma market: What does the future hold for the industry?

Anthony Morton-Small
Managing Director
Vista Health Pte Ltd, Singapore

11.00am – 11.30am

Coffee & Tea Break

11.30am – 1.00pm

SESSION 3 - The challenges and opportunities of digitalization and technological innovation and the need for sustainability from end to end.

A fourth industrial revolution is unfolding. Much has been undertaken already by industry players to leverage the power of digital and analytics but much still lies ahead. What are the innovation opportunities around existing molecules (i.e., value-added medicines)? What incentives exist to encourage the expansion of manufacturing in these areas? Are recovery funds available to support green and digital production and technology transformation? How do national pricing policies reflect these developments and impact the sustainability from end to end during these demanding times? During this session, subject matter experts will discuss the impact that new technologies have on the generic and biosimilar medicines industry and the ability of the industry to provide affordable medicines to patients around the world.

Chair of the Session

Anthony Lakavage
Senior Vice President, Global External Affairs Secretary
USP Board of Trustees & Convention
United States of America

Speakers of the Session

Trends of digitalization and technological innovation

Dinesh Sampath Rangaraj
Senior Vice President, Global Client Lead
Frost & Sullivan, Malaysia

Experiences and lessons learned from adopting Industry 4.0

Abram Ziegelaar
Vice President, Head of Operational Technology
B. Braun, Malaysia

Impact on the global off-patent market of:
-the pricing pressure coupled with green & digital transition requirements and
-the growth opportunities for biosimilar and complex generic medicines

Swati Chaudhary
Senior Director
Sales, South Asia,
IQVIA, India

Preserving patient access in an increasingly challenging market environment: A global company's perspective

Mathew Thomas
Head of Corporate Affairs – Emerging Asia
Viatris Private Limited, Singapore

1.00pm – 2.00pm

Networking Lunch + WHO video presentation on the WHO-South Korea biomanufacturing training hub initiative

2.00pm – 3.30pm

SESSION 4 - Defining effective strategies to advance access to treatments for Non-Communicable Diseases.

Non-communicable diseases (NCDs) are one of the most significant challenges in global health today. Greater longevity is also associated with an increase in non-communicable diseases, especially chronic conditions. Reducing NCDs is one of the key targets of the UN Sustainable Development Goals. This session will discuss effective strategies to advance access to treatments for NCDs and the role of generic and biosimilar medicines in contributing to the control of NCDs.

Chair of the Session

Suzette Kox
Secretary General
International Generic and Biosimilar Medicines Association (IGBA), Switzerland

Speakers of the Session

NCD management: Perspective from the demand and prevention angle

Dr. Feisul Idzwan Bin Mustapha
Deputy Director
Disease Control Division
Ministry of Health, Malaysia

Advancing access to NCD treatments: A company’s perspective

Dr. Arun Chandavarkar
Managing Director
Biocon Biologics Limited, India

Market access for NCD treatments in selected APAC countries

Meiyoke Soo
Chief Executive Officer Senior Vice-President
Commercial Operations
Fresenius Kabi Asia Pacific, Hong Kong

Patients lived experiences with NCDs: The perspective of a patient advocacy group

Chee Yoke Ling
Executive Director
Third World Network, Malaysia

3.30pm – 4.00pm

Coffee & Tea Break

4.00pm – 5.30pm

SESSION 5 - The importance of globally resilient supply chain and trade facilitating measures.

The COVID-19 pandemic has focused global attention on the complexity and importance of the pharmaceutical global supply chain. In response to concerns about the resilience of this supply chain, many governments are attempting to strengthen their efforts to build local manufacturing competency and on-/near-shore supply for a variety of medicines. A balanced approach on these issues, both in terms of recognizing the criticality of the global supply chain while fulfilling local market needs, will be vital to help the industry manage its competitiveness and ensure supply security across markets. This session will address emerging opportunities and challenges for the global pharmaceutical supply chain as well as the importance of barrier-free trade and the rise of national policies that directly impact it.

Chair of the Session

Jonathan Kimball
Vice President
Trade, International Affairs & Strategic Initiatives
Association for Accessible Medicines (AAM), United States of America
Vice-Chair, International Generic and Biosimilar Medicines Association (IGBA), Switzerland

Speakers of the Session

The role of the world trade organization in ensuring barrier-free trade during a pandemic and beyond

Nora Neufield
Counsellor
Market Access Division
World Trade Organization (WTO), Switzerland

**API everywhere:
Localization of API production**

Srividya Jagannathan
Sector Lead for Lifesciences and Medtech
International Finance Corporation (IFC), United States of America

Delivering medicines during a pandemic-lessons learned & recommendations: A logistics company perspective

Wilman Low
Senior Director
DHL Supply Chain India Pvt. Ltd, India

Supplying medicines during a pandemic-lessons learned & recommendations: a manufacturer's perspective

Ravi Prakash Mathur
Vice President
Supply Chain Management
Dr. Reddy's Laboratories, India

7.30pm - 10.00pm

Welcoming Dinner @ Taman Mahsuri, Royal Chulan KL

9 September 2022 (Friday) - Half Day

Time	Agenda
8.00am - 9.00am	Welcoming Coffee & Tea
9.00am - 9.30am	Keynote Address by YBrs. Puan Norhaliza Binti A Halim, Senior Director, Pharmaceutical Services Programme, Ministry of Health, Malaysia
9.30am - 11.00am	SESSION 6 - The impact of regulatory agility, reliance and harmonization on access to medicines for patients around the world.
	The pandemic has highlighted more than ever the need for regulatory efficiency and harmonization. This session takes stock of the ASEAN harmonization process regarding mutual recognition agreements of bioequivalence studies and mutual recognition of GMP inspections, the status of a regulatory framework for global development, the WHO initiative on regulatory reliance and early findings from the International Coalition of Medicines Regulatory Authorities' pilot projects for collaborative hybrid inspections and collaborative assessment.

Chair of the Session

Dr. Nicholas Cappuccino
Principal Pharmaceutical Regulatory Consultant
CEO of Pharmaceutical Intellectual Resource Services LLC, United States of America
Chair Science Committee, International Generic and Biosimilar Medicines Association (IGBA), Switzerland

Speakers of the Session

Progress of the ASEAN harmonization efforts with regards to the signed mutual recognition agreements on GMP and bioequivalence

Dr. Roshayati Binti Mohamad Sani
Director
National Pharmaceutical Regulatory Agency (NPRA), Malaysia

Regulatory collaboration in progress: Insights into the international coalition of medicines regulatory authorities pilot projects on collaborative hybrid inspections and collaborative assessment

Dr. Theresa Mullin
Associate Director
Center for Drug Evaluation and Research
Strategic Initiatives
U.S. Food and Drug Administration, United States of America

International convergence in the field of bioequivalence: enabling global development and access to generic medicines

Dr. Clare Rodrigues
Regulatory Consultant
Health Sciences Authority (HSA), Singapore &
Co-Chair of the IPRP BE Working group and Member of ICH M13

Development of global dossiers in light of harmonization

Dr. Susana Almeida
Clinical Development and Safety Director
Medicines for Europe, Belgium

11.00am – 11.15am

Coffee & Tea Break + WHO video presentation on the WHO-South Korea biomanufacturing training hub initiative

11.15am – 12.15pm

SESSION 7 - Panel discussion on the vision of the industry in a post pandemic environment

Chair of the Session

Chair: A representative from McKinsey

Panelists of the Session

Leonard Ariff Bin Abdul Shatar
Group Managing Director
Duopharma Biotech Berhad, Malaysia

Jose Luis Cardenas
Senior Director
Government Affairs & Market Access LATAM
Teva Pharmaceutical Industries Ltd, Chile

Rabbur Reza
Chief Operating Officer
Beximco Pharmaceuticals, Bangladesh

Jeff Bote
Country Manager
Viatris, Malaysia

12.15pm - 12.30pm

Closing Session

12.30pm - 2.30pm

Friday Prayers, Networking Lunch & End of Conference

CONTACT HELPDESK

We are ready to answer any inquiries.

Tel: (+6) 03-79319003

Email us: igbaconference2022@gmail.com

Website: www.igbaconference2022.com

Link to Ticket purchase: [Click here](#)

Get 10% off when you purchase the ticket before 31st July 2022.

Use the promo code: 10IGBAMOPI



INTERNATIONAL GENERIC AND
BIOSIMILAR MEDICINES ASSOCIATION

